Literature DB >> 9683787

Expression of insulin-like growth factor 2 mRNA in human gastric cancer.

T Shiraishi1, M Mori, M Yamagata, M Haraguchi, H Ueo, K Sugimachi.   

Abstract

Insulin-like growth factor 2 (IGF2) stimulates cell proliferation and development in normal human growth. In several human cancers, the IGF2 gene is overexpressed and is thus considered to be a growth factor for tumors mediated through both the paracrine and autocrine pathways. However, the significance of IGF2 mRNA expression in gastric cancer has yet to be clarified. We semi-quantitatively measured the expression of IGF2 mRNA in 57 Japanese cases of gastric cancer by means of the reverse transcription polymerase chain reaction and also analyzed the relation between the IGF2 expression status and other clinicopathologic factors. We also performed immunohistochemical staining for IGF2. In 41 of 57 cases (72%), the expression of IGF2 mRNA was greater in tumor tissue (T) than in normal tissue (N). The average tumor/normal (T/N) expression ratio of IGF2 mRNA corrected for that of control gene mRNA was 1.42, while ranging from 0.36 to 3.65. The T/N ratio of infiltrative-type cancers was greater than that of expanding-type cancers (p<0.05). The cases with lymphatic permeation showed a greater T/N ratio than those without lymphatic permeation in expanding-type cancers (p<0. 05). Immunohistochemical staining revealed IGF2 to be detected in cancer cells themselves, especially at the margin of the cancer tissue. The IGF2 gene may thus play an important role in lymph vessel permeation especially in expanding-type gastric cancers.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9683787     DOI: 10.3892/ijo.13.3.519

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  7 in total

1.  Association between IRS-2 G1057D polymorphism and risk of gastric cancer.

Authors:  Xiao-Mei Zhao; Jie Chen; Li Yang; Xuan Luo; Lin-Lin Xu; Dong-Xiao Liu; Su-Lan Zhai; Ping Li; Xue-Rong Wang
Journal:  World J Gastrointest Oncol       Date:  2012-01-15

2.  Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts.

Authors:  Y Min; Y Adachi; H Yamamoto; A Imsumran; Y Arimura; T Endo; Y Hinoda; C-T Lee; S Nadaf; D P Carbone; K Imai
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

3.  Clinical significance of IGF1R gene expression in patients with Stage II/III gastric cancer who receive curative surgery and adjuvant chemotherapy with S-1.

Authors:  Koji Numata; Takashi Oshima; Kentaro Sakamaki; Kazue Yoshihara; Toru Aoyama; Tsutomu Hayashi; Takanobu Yamada; Tsutomu Sato; Haruhiko Cho; Manabu Shiozawa; Takaki Yoshikawa; Yasushi Rino; Chikara Kunisaki; Makoto Akaike; Toshio Imada; Munetaka Masuda
Journal:  J Cancer Res Clin Oncol       Date:  2015-09-03       Impact factor: 4.553

4.  IGF-II promoter methylation and ovarian cancer prognosis.

Authors:  A C Beeghly; D Katsaros; A L Wiley; I A Rigault de la Longrais; A T Prescott; H Chen; M Puopolo; T J Rutherford; H Yu
Journal:  J Cancer Res Clin Oncol       Date:  2007-06-14       Impact factor: 4.553

5.  A novel RNA-binding protein, Ossa/C9orf10, regulates activity of Src kinases to protect cells from oxidative stress-induced apoptosis.

Authors:  Masamitsu Tanaka; Kazuki Sasaki; Reiko Kamata; Yukari Hoshino; Kazuyoshi Yanagihara; Ryuichi Sakai
Journal:  Mol Cell Biol       Date:  2008-11-17       Impact factor: 4.272

6.  [Screening of metastasis-related microRNAs in the large-cell lung cancer cell lines with different metastastic potentials].

Authors:  Weishan Lu; Shujun Li; Bin Liu; Yang Li; Meng Luo; Liya Sun; Jiacong You; Qinghua Zhou
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2011-11

7.  Loss of imprinting of insulin-like growth factor 2 is associated with increased risk of lymph node metastasis and gastric corpus cancer.

Authors:  Yang Lu; Ping Lu; Zhi Zhu; Huimian Xu; Xike Zhu
Journal:  J Exp Clin Cancer Res       Date:  2009-09-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.